FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594944671> ?p ?o ?g. }

• W2594944671 abstract "Hypertension is a common early adverse event of anti-angiogenic treatment of cancer and may associate with treatment response. However, blood pressure measurement as a surrogate response biomarker has methodological limitations, and predictive biomarkers of angiogenesis inhibitors are lacking. In disease associated with hypertension, vasoactive peptides have been linked to cardiovascular pressure load. Here, we have explored potential associations between circulating levels of vasoactive peptides and tumor response during bevacizumab-containing treatment of colorectal cancer.Metastatic colorectal cancer (mCRC) patients with available best objective response (ORR) and time to tumor progression (TTP) data were included from a randomized clinical trial investigating maintenance therapy after first line chemotherapy plus bevacizumab. Midregional-pro-adrenomedullin (MR-proADM), midregional-pro-atrial-natriuretic-peptide (MR-proANP), and C-terminal-prepro-vasopressin (Copeptin) vasoactive peptide concentrations were measured in plasma at baseline and after 6 weeks of chemotherapy and bevacizumab treatment (n = 97). We determined associations among clinical outcome (ORR and TTP), peptide levels, and hypertension (NCI-CTCAE 4.0 criteria), using Spearman's test, multiple linear regression, and Mann-Whitney's test.Increasing levels of vasoactive peptides from baseline and after six weeks of treatment were associated with improved treatment outcome (MR-proADM: ORR, p = .0003; TTP, p = .05; MR-proANP: ORR, p = .05; TTP, p = .03; Copeptin: ORR, p = .10; TTP, p = .02). Patients with increasing levels of all three peptides (n = 28) versus increasing levels of one or two peptides (n = 59) showed a median TTP of 284 and 225 d, respectively (p = .02).Our results suggest that increasing systemic levels of vasoactive peptides associate with improved tumor response and TTP in mCRC patients treated with a bevacizumab-containing regimen. These findings support the proposed link between the tumor vasculature and the cardiovascular system of the host. This should motivate further studies that investigate the potential role of vasoactive peptides as a novel class of dynamic biomarkers in the treatment of cancer." @default.
• W2594944671 created "2017-03-23" @default.
• W2594944671 creator A5009891370 @default.
• W2594944671 creator A5018881195 @default.
• W2594944671 creator A5061921179 @default.
• W2594944671 creator A5067901779 @default.
• W2594944671 creator A5077315656 @default.
• W2594944671 creator A5086839394 @default.
• W2594944671 date "2017-03-17" @default.
• W2594944671 modified "2023-09-24" @default.
• W2594944671 title "Vasoactive peptides associate with treatment outcome ofbevacizumab-containing therapy in metastatic colorectal cancer" @default.
• W2594944671 cites W2000262264 @default.
• W2594944671 cites W2010986737 @default.
• W2594944671 cites W2022792673 @default.
• W2594944671 cites W2042471252 @default.
• W2594944671 cites W2042884540 @default.
• W2594944671 cites W2051603178 @default.
• W2594944671 cites W2056587840 @default.
• W2594944671 cites W2075457174 @default.
• W2594944671 cites W2097799276 @default.
• W2594944671 cites W2101397596 @default.
• W2594944671 cites W2109308366 @default.
• W2594944671 cites W2111790572 @default.
• W2594944671 cites W2113652101 @default.
• W2594944671 cites W2122074158 @default.
• W2594944671 cites W2126573891 @default.
• W2594944671 cites W2127827980 @default.
• W2594944671 cites W2133593325 @default.
• W2594944671 cites W2141660542 @default.
• W2594944671 cites W2144352652 @default.
• W2594944671 cites W2146147508 @default.
• W2594944671 cites W2156557061 @default.
• W2594944671 cites W2157769714 @default.
• W2594944671 cites W2158303916 @default.
• W2594944671 cites W2162006440 @default.
• W2594944671 cites W2167798736 @default.
• W2594944671 doi "https://doi.org/10.1080/0284186x.2017.1302098" @default.
• W2594944671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28303751" @default.
• W2594944671 hasPublicationYear "2017" @default.
• W2594944671 type Work @default.
• W2594944671 sameAs 2594944671 @default.
• W2594944671 citedByCount "8" @default.
• W2594944671 countsByYear W25949446712018 @default.
• W2594944671 countsByYear W25949446712019 @default.
• W2594944671 countsByYear W25949446712020 @default.
• W2594944671 countsByYear W25949446712022 @default.
• W2594944671 crossrefType "journal-article" @default.
• W2594944671 hasAuthorship W2594944671A5009891370 @default.
• W2594944671 hasAuthorship W2594944671A5018881195 @default.
• W2594944671 hasAuthorship W2594944671A5061921179 @default.
• W2594944671 hasAuthorship W2594944671A5067901779 @default.
• W2594944671 hasAuthorship W2594944671A5077315656 @default.
• W2594944671 hasAuthorship W2594944671A5086839394 @default.
• W2594944671 hasBestOaLocation W25949446711 @default.
• W2594944671 hasConcept C121608353 @default.
• W2594944671 hasConcept C126322002 @default.
• W2594944671 hasConcept C143998085 @default.
• W2594944671 hasConcept C170493617 @default.
• W2594944671 hasConcept C2775915353 @default.
• W2594944671 hasConcept C2776370428 @default.
• W2594944671 hasConcept C2776694085 @default.
• W2594944671 hasConcept C2777152744 @default.
• W2594944671 hasConcept C2777802072 @default.
• W2594944671 hasConcept C2778198053 @default.
• W2594944671 hasConcept C2779311642 @default.
• W2594944671 hasConcept C526805850 @default.
• W2594944671 hasConcept C71924100 @default.
• W2594944671 hasConceptScore W2594944671C121608353 @default.
• W2594944671 hasConceptScore W2594944671C126322002 @default.
• W2594944671 hasConceptScore W2594944671C143998085 @default.
• W2594944671 hasConceptScore W2594944671C170493617 @default.
• W2594944671 hasConceptScore W2594944671C2775915353 @default.
• W2594944671 hasConceptScore W2594944671C2776370428 @default.
• W2594944671 hasConceptScore W2594944671C2776694085 @default.
• W2594944671 hasConceptScore W2594944671C2777152744 @default.
• W2594944671 hasConceptScore W2594944671C2777802072 @default.
• W2594944671 hasConceptScore W2594944671C2778198053 @default.
• W2594944671 hasConceptScore W2594944671C2779311642 @default.
• W2594944671 hasConceptScore W2594944671C526805850 @default.
• W2594944671 hasConceptScore W2594944671C71924100 @default.
• W2594944671 hasFunder F4320321929 @default.
• W2594944671 hasFunder F4320322581 @default.
• W2594944671 hasFunder F4320323766 @default.
• W2594944671 hasFunder F4320326807 @default.
• W2594944671 hasFunder F4320335417 @default.
• W2594944671 hasLocation W25949446711 @default.
• W2594944671 hasLocation W25949446712 @default.
• W2594944671 hasOpenAccess W2594944671 @default.
• W2594944671 hasPrimaryLocation W25949446711 @default.
• W2594944671 hasRelatedWork W2067097538 @default.
• W2594944671 hasRelatedWork W2077615248 @default.
• W2594944671 hasRelatedWork W2114024295 @default.
• W2594944671 hasRelatedWork W2302472031 @default.
• W2594944671 hasRelatedWork W2326197106 @default.
• W2594944671 hasRelatedWork W2339289555 @default.
• W2594944671 hasRelatedWork W2345567628 @default.
• W2594944671 hasRelatedWork W2755443795 @default.
• W2594944671 hasRelatedWork W2914832607 @default.
• W2594944671 hasRelatedWork W3203896279 @default.
• W2594944671 isParatext "false" @default.

• next